Xendo's Integrated Drug Development concept accelerates biopharmaceutical development projects

Xendo has joined forces with Selexis S.A. and now offers the biopharmaceutical industry their newly developed Integrated Drug Development concept.

Using the established Selexis SURE Cell Line Development℠ program^TM for CHO and HEK cell lines, a time saving of at least 4 to 6 months is within reach, on top of increased cost efficiency. By including the high level Regulatory and QA compliance expertise into the project, a fully scalable cGMP compliant process is warranted. As a consequence the development phase will result in successful manufacturing of pre-clinical and phase I clinical material.

For more information download the press release or contact Ard Tijsterman at +31 71 524 40 00.

Xendo - Selexis press release 2008 November 14